You have 9 free searches left this month | for more free features.

anti-CTLA4 antibody

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)

Terminated
  • Non-small Cell Lung Cancer
  • Saint Petersburg, Florida
  • +2 more
Oct 22, 2022

Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Pittsburgh (Nivolumab, Relatlimab, Ipilimumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 31, 2022

Melanoma (Skin), Cutaneous Melanoma, Adult Disease Trial in France, Spain, United States (ANV419, Pembrolizumab, Ipilimumab)

Recruiting
  • Melanoma (Skin)
  • +4 more
  • Bloomington, Minnesota
  • +7 more
Jan 31, 2023

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Synovial Sarcoma Trial in New York (ipilimumab)

Terminated
  • Synovial Sarcoma
  • ipilimumab
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Jun 23, 2021

Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 17, 2022

Skin Health and Quality of Life in Patients Receiving

Not yet recruiting
  • Lung Cancer
  • +7 more
  • EQ-5D-5L questionnaire
  • +2 more
  • Roma, Italy
    Roberto Iacovelli
May 17, 2023

Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)

Active, not recruiting
  • Hepatocellular Carcinoma
  • AK104 lenvatinib
  • AK104
  • Hangzhou, Zhejiang, China
    The first affilited hospital zhejiang university school of medci
Oct 17, 2022

Urinary Bladder Tumors Trial in San Antonio (AGEN1884, AGEN2034, Cisplatin)

Active, not recruiting
  • Urinary Bladder Neoplasms
  • San Antonio, Texas
    Mays Cancer Center
Mar 11, 2022

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion;Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Active, not recruiting
  • Anatomic Stage II Breast Cancer AJCC v8
  • +16 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Trial (SBRT, Cadonilimab)

Not yet recruiting
  • Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
  • (no location specified)
Feb 8, 2023

Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland

Not yet recruiting
  • Locally Advanced Thyroid Gland Anaplastic Carcinoma
  • +2 more
  • Chicago, Illinois
  • +1 more
Jul 7, 2022

Solid Tumor, Adult Trial in Australia, Hong Kong (CS1002, CS1003)

Completed
  • Solid Tumor, Adult
  • Albury, New South Wales, Australia
  • +9 more
Dec 15, 2022

Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Atlanta

Not yet recruiting
  • Castration-Sensitive Prostate Carcinoma
  • +2 more
  • Atlanta, Georgia
  • +1 more
Feb 8, 2023

Recurrent or Metastatic Cervical Cancer Trial in Changsha, Hangzhou (AK104, Bevacizumab, Paclitaxel)

Active, not recruiting
  • Recurrent or Metastatic Cervical Cancer
  • AK104
  • +3 more
  • Changsha, Hunan, China
  • +1 more
Mar 28, 2022

Advanced Solid Tumor Trial in Zhengzhou, Linyi (BAT4706 Injection, BAT1308 Injection)

Not yet recruiting
  • Advanced Solid Tumor
  • BAT4706 Injection
  • BAT1308 Injection
  • Zhengzhou, Henan, China
  • +2 more
Nov 14, 2023

Breast Cancer, Head Neck Cancer, Squamous Cell Carcinoma Trial in Canada, United States (INT230-6, anti-PD-1 antibody,

Active, not recruiting
  • Breast Cancer
  • +10 more
  • Los Angeles, California
  • +7 more
Jun 21, 2022

Advanced Malignant Tumors Trial in Shanghai (AK104, AK117, Capecitabine tablets)

Recruiting
  • Advanced Malignant Tumors
  • Shanghai, China
    Shanghai Renji Hospital
Aug 9, 2022

Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7 Trial in Houston (biological, other,

Completed
  • Metastatic Carcinoma in the Liver
  • +4 more
  • Durvalumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Esophageal Squamous Cell Carcinoma Trial (QL1706)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Aug 4, 2022

Advanced Lung Carcinoma, Advanced Malignant Solid Tumor, Malignant Adrenal Gland Tumor Trial in Houston (Anti-CTLA4 Monoclonal

Recruiting
  • Advanced Lung Carcinoma
  • +16 more
  • Anti-CTLA4 Monoclonal Antibody BMS-986218
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 20, 2022